



IRB#16363
Phase 2
INCB050465
plus
Ruxolitinib

IRB# 19142
Open-Label, Ph 2a/2b
of KRT-232 in Subjects
with Primary
Myelofibrosis (MF) ,
Post-Polycythemia
Vera MF, or Post-
Essential
Thrombocythemia MF
who have failed prior
treatment with a JAK
Inhibitor

IRB# 20736
Randomized,
Controlled Phase
3 Study of
Pacritinib Versus
Physician's Choice
in Patients with
Primary
Myelofibrosis
(MF), Post
Polycythemia
Vera MF, or Post
Essential
Thrombocythemia
MF with Severe
Thrombocytopeni
a

IRB# 22131
Study
coming soon

IRB# 17155
Phase 1 of
DCC-2618 in
Advanced
Malignancies

IRB# 21165
Study
coming soon

IRB# 21999
Study
coming soon

IRB# 22252
Study coming
soon

IRB#15977
Non
Treatment
National
MDS Study
(ECOG/ACRI
N)

Cross
Disease Trial
- IRB# 19992
- EAY131
(MATCH)

Key

- Open for Enrollment
- In Development
- Enrollment on Hold